Supplementary Data from Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> Trial — Judith Trotman (2024) | RDL Network
Supplementary Data from Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> Trial
Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey Matous, D. Blair Macdonald, Constantine S. Tam, Olivier Tournilhac, Shuo Ma, Steven P. Treon, Albert Oriol, Jerry Ping, Eva M. Briso, Israel Arango‐Hisijara, Meletios A Dimopoulos
Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey Matous, D. Blair Macdonald, Constantine S. Tam, Olivier Tournilhac, Shuo Ma, Steven P. Treon, Albert Oriol, Jerry Ping, Eva M. Briso, Israel Arango‐Hisijara, Meletios A Dimopoulos
Dustin J. Flanagan, Nick Barker, Natasha S. Di Costanzo, Elizabeth A. Mason, Austin Gurney, Valérie S. Méniel, Sarah Koushyar, Chloe R. Austin, Matthias Ernst, Helen Pearson, Alex Boussioutas, Hans Clevers, Toby J. Phesse, Elizabeth Vincan
Dustin J. Flanagan, Nick Barker, Natasha S. Di Costanzo, Elizabeth A. Mason, Austin Gurney, Valérie S. Méniel, Sarah Koushyar, Chloe R. Austin, Matthias Ernst, Helen Pearson, Alex Boussioutas, Hans Clevers, Toby J. Phesse, Elizabeth Vincan
Gabriele Galliverti, Stephan Wullschleger, Mélanie Tichet, Dhaarini Murugan, Nadine Zangger, Wesley Horton, Alan J. Korman, Lisa M. Coussens, Melody A. Swartz, Douglas Hanahan
Discussion(0)
No comments yet. Be the first to comment.